Lilly is accelerating growth through strong revenue, pipeline progress, and acquisitions, while Pfizer is rebuilding after COVID-era declines and facing major patent-cliff pressure.
Eli Lilly delivered consecutive blowout quarters with strong revenue and earnings beats, driven by Mounjaro and Zepbound dominance, while institutional investors accumulate shares despite a year-to-date pullback.